DesignerAntibiotics
Towards the prevention of aminoglycoside antibiotic-related deafness
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0DesignerAntibiotics project word cloud
Explore the words cloud of the DesignerAntibiotics project. It provides you a very rough idea of what is the project "DesignerAntibiotics" about.
Project "DesignerAntibiotics" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITY COLLEGE LONDON
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 251˙857 € |
| EC max contribution | 251˙857 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2015 |
| Funding Scheme | MSCA-IF-GF |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-02-13 to 2020-02-12 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITY COLLEGE LONDON | UK (LONDON) | coordinator | 251˙857.00 |
| 2 | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | US (STANFORD) | partner | 0.00 |
Map
Project objective
Aminoglycosides are critically important antimicrobials used in the treatment of life-threatening infections. A major drawback of usage is hearing loss caused by irreversible damage to the inner ear (ototoxicity). Ototoxicity occurs in ~20% of patients and ~100% of patients with the m.1555A>G mitochondrial DNA mutation. The largest EU patient group exposed to aminoglycosides are children in neonatal intensive care and the effect of hearing loss during infancy is particularly profound as it impedes language acquisition. Thus, there is an urgent need to develop safer aminoglycoside antibiotics. Ototoxicity limits usage despite the antibacterial potency and low incidence of drug resistance provided by this class of antibiotics. Economically, the annual EU cost incurred by drug resistant infections amounts to €1.5 billion, and the cost of hearing impairment is estimated to be €78 billion. Moreover, 25,000 EU patients die annually as a result of infections caused by resistant bacteria and 22.5 million suffer from hearing impairment, with 2 million profoundly deaf.
Stanford research recently published in the Journal of Clinical Investigation has shown that it is possible to chemically modify aminoglycosides to diminish ototoxicity while maintaining antibacterial activity. Through a novel collaboration between Stanford and University College London (UCL), the aim of this research is to use a results-guided drug design approach to develop the next generation of safer aminoglycoside antibiotics. For this work, the candidate will have access to 15 novel patented aminoglycoside compounds, crystallography data, murine in vitro and in vitro models of ototoxicity, and a rare biobank of cells from patients with the m.1555A>G mutation. This work will build upon the candidate’s Distinction Masters of Research structural biology experience at Imperial College London, and UCL PhD and recent first-author publication in Human Molecular Genetics related to aminoglycoside ototoxicity.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DESIGNERANTIBIOTICS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DESIGNERANTIBIOTICS" are provided by the European Opendata Portal: CORDIS opendata.